Leveraging biomarkers and diagnostics in personalized medicine is becoming increasingly important in the fight against cancer. Bristol Myers Squibb is pioneering research to better understand cancer biology and its intersection with the immune system.
We are investigating a number of different biomarkers that may help match the right patients with the right treatments at the right time. Select the biomarker name for more information.
Biomarkers indicative of host environment:
Microbiome | Germline Mutations